ReviewStem cell research & therapy2025
Harnessing mesenchymal stem/stromal cells-based therapies for rheumatoid arthritis: mechanisms, clinical applications, and microenvironmental interactions.
Review in Stem cell research & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Immunomodulatory efficacy of culture condition-dependent modulation of mesenchymal stem cells.Stem cell research & therapy · 2026Review
- Cellular crosstalk and signaling networks in the rheumatoid arthritis synovial microenvironment.Journal of translational medicine · 2026Review
- Wenyang Yishen Tongluo prescription synergizes with bone marrow mesenchymal stem cells to alleviate rheumatoid arthritis via inhibiting IL-6.Journal of molecular histology · 2026Article
- Cellular stress, cell death, and extracellular vesicles: redefining the therapeutic landscape of rheumatoid arthritis.Clinical rheumatology · 2026Review
- Systemic regulation of rheumatoid arthritis by mesenchymal stem cells: from immune homeostasis to microbiota modulation.Frontiers in immunology · 2026Review
- Tissue-Resident Memory T Cells in Rheumatoid Immune Diseases: Pathogenic Mechanisms and Therapeutic Strategies.Biomedicines · 2025Review
- Immunocyte-derived extracellular vesicles in osteoimmunology: mechanisms, disease contexts, and translational prospects.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease characterized by persistent joint inflammation and progressive bone destruction. Current conventional treatments, including nonsteroidal anti-inflammatory drugs, glucocorticoids, and disease-modifying antirheumatic drugs, often fail to achieve sustained remission in many patients. Mesenchymal stem/stromal cells (MSCs) have emerged as a promising therapeutic option for RA due to their immunomodulatory and regenerative properties. However, challenges such as poor migration and homing, low survival rate, heterogeneity, and impaired potency under pathological microenvironment need to be resolved to promote the use of MSCs in the clinic in the future. This review comprehensively examines the role of MSCs and their interaction with the microenvironment in the treatment of RA. We analyze completed and ongoing clinical trials involving MSC-based therapies for RA, summarize strategies to enhance the therapeutic effect of MSCs on RA, and propose standardized parameters to optimize clinical applications. By addressing these critical aspects, this review aims to advance the development of MSC-based therapies for RA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.